Indicators
Indicators
Value
Direction
MACD(12,26,9)
-4.328
Neutral
RSI(14)
37.000
Neutral
STOCH(KDJ)(9,3,3)
13.482
Oversold
ATR(14)
3.037
High Vlolatility
CCI(14)
-127.404
Sell
Williams %R
78.967
Sell
TRIX(12,20)
-0.013
Sell
StochRSI(14)
38.397
Buy
Novo Nordisk A/S
NVO47.640USD
+4.335+10.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
160.50BMarket Cap
13.67P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Novo Nordisk A/S
Currency: USD Updated: 2026-02-06Key Insights
Novo Nordisk A/S's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 57.79.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novo Nordisk A/S's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative-
Novo Nordisk A/S Highlights
StrengthsRisks
Novo Nordisk A/S is a Danish multinational pharmaceutical firm headquartered in Bagsværd, with manufacturing facilities across nine countries and affiliates or offices in five others. The company is predominantly controlled by its majority shareholder, Novo Holdings A/S, which owns approximately 28.1% of its shares and a majority of its voting rights.
Novo Nordisk specializes in the production and marketing of pharmaceutical products and services, focusing primarily on diabetes care medications and devices. Among its key products is semaglutide, utilized for diabetes treatment under the brand names Ozempic and Rybelsus, as well as for obesity treatment under the brand name Wegovy. The company also engages in hemostasis management, growth hormone therapy, and hormone replacement therapy, producing numerous drugs under various brand names such as Levemir, Tresiba, NovoLog, Novolin R, NovoSeven, NovoEight, and Victoza.
Employing over 48,000 individuals worldwide, Novo Nordisk distributes its products in 168 countries. The corporation was formed in 1989 from a merger of two Danish companies with origins tracing back to the 1920s. The Novo Nordisk logo features the Apis bull, a sacred animal from ancient Egypt, represented by the hieroglyph 𓃒. Novo Nordisk is also a full member of the European Federation of Pharmaceutical Industries and Associations.
Recognized for its workplace culture, the company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, later ranking 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was acclaimed as the most sustainable company globally by Corporate Knights, while its spin-off, Novozymes, secured the fourth position. The company is a leader in the FTSE4Good Index and stands as the only European firm in the top ten list. As the largest pharmaceutical company in Denmark, Novo Nordisk's market capitalization surpassed the GDP of Denmark's domestic economy in 2023, making it the highest valued company in Europe, with net sales reaching US$42.121 billion in 2024.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.54% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 46.70B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 50.19%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 50.19%.
Undervalued
The company’s latest PE is 13.67, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 310.22M shares, decreasing 4.87% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 437.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.63.
Analyst Rating
Based on
12
analysts
Hold
Current Rating
58.565
Target Price
+24.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Novo Nordisk A/S is 8.91, ranking 30 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 12.34B, representing a year-over-year increase of 0.69%, while its net profit experienced a year-over-year increase of 3.84%.
Score
Financials
6.19
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.68
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
8.66
Novo Nordisk A/S's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Novo Nordisk A/S is 7.37, ranking 76 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 13.67, which is 269.82% below the recent high of 50.57 and 9.03% above the recent low of 12.44.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 77/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Novo Nordisk A/S is 6.17, ranking 134 out of 159 in the Pharmaceuticals industry. The average price target is 53.39, with a high of 90.39 and a low of 41.90.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Hold
Current Rating
58.565
Target Price
+24.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Novo Nordisk A/S
NVO
12
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Novo Nordisk A/S is 7.02, ranking 84 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 60.12 and the support level at 39.20, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
49.480
Sell
MA10
55.336
Sell
MA20
57.726
Sell
MA50
53.206
Sell
MA100
53.452
Sell
MA200
58.582
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Novo Nordisk A/S is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 9.22%, representing a quarter-over-quarter increase of 1.51%. The largest institutional shareholder is Ken Fisher, holding a total of 10.32M shares, representing 0.31% of shares outstanding, with 13.18% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
Fidelity Management & Research Company LLC
Folketrygdfondet
Managed Account Advisors LLC
Fayez Sarofim & Co.
Everett Harris & Co.
Parametric Portfolio Associates LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Novo Nordisk A/S is 6.67, ranking 50 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.71. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.72
VaR
+3.13%
240-Day Maximum Drawdown
+52.35%
240-Day Volatility
+54.06%
Return
Best Daily Return
60 days
+9.92%
120 days
+9.92%
5 years
+17.23%
Worst Daily Return
60 days
-14.64%
120 days
-14.64%
5 years
-21.83%
Sharpe Ratio
60 days
+0.59
120 days
-0.04
5 years
+0.37
Risk Assessment
Maximum Drawdown
240 days
+52.35%
3 years
+70.50%
5 years
+70.50%
Return-to-Drawdown Ratio
240 days
-0.91
3 years
-0.18
5 years
+0.08
Skewness
240 days
-1.22
3 years
-0.83
5 years
-0.91
Volatility
Realised Volatility
240 days
+54.06%
5 years
+37.76%
Standardised True Range
240 days
+4.68%
5 years
+4.04%
Downside Risk-Adjusted Return
120 days
-5.05%
240 days
-5.05%
Maximum Daily Upside Volatility
60 days
+49.61%
Maximum Daily Downside Volatility
60 days
+54.36%
Liquidity
Average Turnover Rate
60 days
+0.35%
120 days
+0.29%
5 years
--
Turnover Deviation
20 days
+162.61%
60 days
+119.11%
120 days
+79.43%
Peer Comparison
Pharmaceuticals
Novo Nordisk A/S
NVO
6.94 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
